Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina

Sigma-1 伴侣介导的体内视网膜神经保护

基本信息

  • 批准号:
    9513208
  • 负责人:
  • 金额:
    $ 16.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2018-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Neurodegenerative eye diseases such as glaucoma cause blindness in a large population in the USA, yet effective treatments are lacking. The ultimate goal of this project is to develop new methods for rescue of retinal neurodegeneration by exploiting a unique endogenous neuroprotective agent, the σ1R chaperone, whose anti-apoptotic properties are being uncovered. Our in vivo studies suggest that the σ1R is ROS (reactive oxygen species)-suppressing and is protective against retinal degeneration in ganglion cells as well as in photoreceptors. This project represents the first study to test the efficacy of the σ1R-mediated retinal neuroprotection by σ1R gene therapy, by overexpressing the σ1R in stem cell-derived photoreceptors to enhance their post-transplantation survival, and by using the sigma-1 receptor knock model (σ1ko) combined with the chronic DBA/2J glaucoma model or rd10 model. In Specific Aim 1, we will examine the impact of the absence of the σ1R for the viability of ganglion cells and photoreceptors in vivo in the DBA/2J model of glaucoma and the rd10 model of RP, respectively. Since we have discovered that ganglion cells of the σ1ko mice are more susceptible to retinal degeneration than the wild type in an acute model, we will further test our finding using a new model crossed with the σ1ko and the chronic glaucoma model of DBA/2J. We will also extend our investigation into a neuroprotective role of the σ1R in retinal photoreceptors, which has yet to be defined, in a new model that we have generated by crossing σ1ko and rd10. Retinal ROS levels will be compared in the presence and absence of the σ1R in these models. In Specific Aim 2, we will test σ1R gene therapy for rescue of retinal degeneration using lentiviruses. To increase the σ1R abundance in the retina, we will transduce the rd10 mouse photoreceptors with lentiviruses harboring the σ1R gene and the Opsin promoter using a technique of subretinal injection. Retinal functions of the transgenic eye overexpressing the σ1R will be compared to that injected with the σ1R-negative mock virus. In Specific Aim 3, we will explore the neuroprotective effect of the σ1R on the post-transplantation survival of stem cell-derived photoreceptors. In stem cell therapy, elevated oxidative stress due to the death of rods, which are active major consumers of oxygen in the retina, imposes detrimental threat to the survival of transplanted photoreceptors. We will overexpress the σ1R in human embryonic stem cell-derived photoreceptors to enhance their survival after transplantation into the rd10 retina. The pro-survival effect of the σ1R on transplanted photoreceptors will be assessed in comparison to the control transplant cells that are transduced with the σ1R-negative mock virus. Ultimately, our finding will lead to new σ1R-targeted therapeutic strategies for rescue of the devastating retinal neurodegenerative diseases.
描述(由申请人提供):神经退行性眼病(如青光眼)在美国造成大量人群失明,但缺乏有效的治疗方法。该项目的最终目标是通过开发独特的内源性神经保护剂σ 1 R分子伴侣来开发新的方法来拯救视网膜神经变性,σ 1 R分子伴侣的抗凋亡特性正在被发现。我们的体内研究表明,σ 1 R是ROS(活性氧)抑制,并保护神经节细胞以及光感受器中的视网膜变性。该项目代表了第一项通过σ 1 R基因治疗,通过在干细胞衍生的光感受器中过表达σ 1 R以提高其移植后存活率,以及通过使用σ-1受体敲除模型(σ 1 ko)结合慢性DBA/2 J青光眼模型或rd 10模型来测试σ 1 R介导的视网膜神经保护的功效的研究。 在具体目标1中,我们将分别在青光眼的DBA/2 J模型和RP的rd 10模型中检查σ 1 R缺失对体内神经节细胞和光感受器活力的影响。由于我们已经发现在急性模型中σ 1 ko小鼠的神经节细胞比野生型更容易发生视网膜变性,我们将使用与σ 1 ko和DBA/2 J的慢性青光眼模型交叉的新模型进一步测试我们的发现。我们还将在我们通过交叉σ 1 ko和rd 10生成的新模型中扩展我们对σ 1 R在视网膜光感受器中的神经保护作用的研究,该作用尚未定义。在这些模型中,将在存在和不存在σ 1 R的情况下比较视网膜ROS水平。 在具体目标2中,我们将使用慢病毒测试σ 1 R基因疗法用于拯救视网膜变性。为了增加视网膜中的σ 1 R丰度,我们将使用视网膜下注射技术用携带σ 1 R基因和视蛋白启动子的慢病毒感染rd 10小鼠光感受器。将过表达σ 1 R的转基因眼的视网膜功能与注射σ 1 R阴性模拟病毒的视网膜功能进行比较。 在具体目标3中,我们将探索σ 1 R对干细胞衍生的光感受器移植后存活的神经保护作用。在干细胞治疗中,由于视杆细胞死亡而引起的氧化应激升高,视杆细胞是视网膜中氧的活跃主要消耗者,对移植的光感受器的存活造成有害的威胁。我们将在人胚胎干细胞衍生的光感受器中过表达σ 1 R,以提高它们移植到rd 10视网膜后的存活率。与用σ 1 R阴性模拟病毒转导的对照移植细胞相比,评估σ 1 R对移植光感受器的促存活作用。 最终,我们的发现将导致新的σ 1 R靶向治疗策略,用于拯救毁灭性的视网膜神经退行性疾病。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Endothelial cells direct human mesenchymal stem cells for osteo- and chondro-lineage differentiation through endothelin-1 and AKT signaling.
  • DOI:
    10.1186/s13287-015-0065-6
  • 发表时间:
    2015-05-01
  • 期刊:
  • 影响因子:
    7.5
  • 作者:
    Tsai TL;Wang B;Squire MW;Guo LW;Li WJ
  • 通讯作者:
    Li WJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lianwang Guo其他文献

Lianwang Guo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lianwang Guo', 18)}}的其他基金

Master epigenetic regulators and retinal degenerative disease
掌握表观遗传调节因子和视网膜退行性疾病
  • 批准号:
    10306197
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
Master epigenetic regulators and retinal degenerative disease
掌握表观遗传调节因子和视网膜退行性疾病
  • 批准号:
    10132335
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
Master epigenetic regulators and retinal degenerative disease
掌握表观遗传调节因子和视网膜退行性疾病
  • 批准号:
    10376193
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery
BET 溴结构域蛋白作为预防血管手术后内膜增生的新表观遗传靶点
  • 批准号:
    10298010
  • 财政年份:
    2020
  • 资助金额:
    $ 16.5万
  • 项目类别:
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction
开发单分子纳米粒子介导的外膜周围药物递送系统,用于持续和靶向抑制开放血管重建后的内膜增生
  • 批准号:
    10305283
  • 财政年份:
    2020
  • 资助金额:
    $ 16.5万
  • 项目类别:
Master epigenetic regulators and retinal degenerative disease
掌握表观遗传调节因子和视网膜退行性疾病
  • 批准号:
    9884774
  • 财政年份:
    2019
  • 资助金额:
    $ 16.5万
  • 项目类别:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
Sigma-1 伴侣介导的体内视网膜神经保护
  • 批准号:
    8346582
  • 财政年份:
    2012
  • 资助金额:
    $ 16.5万
  • 项目类别:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
Sigma-1 伴侣介导的体内视网膜神经保护
  • 批准号:
    8700417
  • 财政年份:
    2012
  • 资助金额:
    $ 16.5万
  • 项目类别:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
Sigma-1 伴侣介导的体内视网膜神经保护
  • 批准号:
    8523895
  • 财政年份:
    2012
  • 资助金额:
    $ 16.5万
  • 项目类别:
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina
Sigma-1 伴侣介导的体内视网膜神经保护
  • 批准号:
    9117592
  • 财政年份:
    2012
  • 资助金额:
    $ 16.5万
  • 项目类别:

相似海外基金

Chaperone-mediated mechanisms of cellular proteostasis
分子伴侣介导的细胞蛋白质稳态机制
  • 批准号:
    10620389
  • 财政年份:
    2023
  • 资助金额:
    $ 16.5万
  • 项目类别:
Exploratoin of Nrf2 activators that potentiate chaperone-mediated autophagy and are useful for the treatment of spinocrebellar ataxia
探索增强伴侣介导的自噬并可用于治疗脊髓小脑共济失调的 Nrf2 激活剂
  • 批准号:
    23K06161
  • 财政年份:
    2023
  • 资助金额:
    $ 16.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular Chaperone-mediated Regulation of Cell Metabolism
分子伴侣介导的细胞代谢调节
  • 批准号:
    10711735
  • 财政年份:
    2023
  • 资助金额:
    $ 16.5万
  • 项目类别:
CHAperone-Mediated Protein degradation (CHAMP) based novel therapy for castration resistant prostate cancer
基于 CHAperone 介导的蛋白质降解 (CHAMP) 的去势抵抗性前列腺癌新疗法
  • 批准号:
    22K09534
  • 财政年份:
    2022
  • 资助金额:
    $ 16.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanistic Insights into small-Ribonucleic Acid Mediated Gene Silencing via Chaperone Repressor of Competence
通过能力伴侣阻遏物对小核糖核酸介导的基因沉默的机制见解
  • 批准号:
    566048-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Regulation of Collagen Type I Expression by Chaperone-Mediated mRNA Remodeling
分子伴侣介导的 mRNA 重塑对 I 型胶原蛋白表达的调节
  • 批准号:
    10202324
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
Regulation of Collagen Type I Expression by Chaperone-Mediated mRNA Remodeling
分子伴侣介导的 mRNA 重塑对 I 型胶原蛋白表达的调节
  • 批准号:
    10582369
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
Interferon regulation by NBR1-driven chaperone-mediated autophagy in stellate cells in liver cancer
NBR1驱动的伴侣介导的肝癌星状细胞自噬对干扰素的调节
  • 批准号:
    10533345
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
Mechanistic Insights into small-Ribonucleic Acid Mediated Gene Silencing via Chaperone Repressor of Competence
通过能力伴侣阻遏物对小核糖核酸介导的基因沉默的机制见解
  • 批准号:
    566817-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 16.5万
  • 项目类别:
    Canadian Graduate Scholarships Foreign Study Supplements
Understanding ER chaperone-mediated RNR regulation
了解 ER 伴侣介导的 RNR 调节
  • 批准号:
    10046751
  • 财政年份:
    2020
  • 资助金额:
    $ 16.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了